Risk of Conversion to Multiple Sclerosis Down With Minocycline

Share this content:
Risk of Conversion to Multiple Sclerosis Down With Minocycline
Risk of Conversion to Multiple Sclerosis Down With Minocycline

THURSDAY, June 1, 2017 (HealthDay News) -- For patients with a first demyelinating event (clinically isolated syndrome), treatment with minocycline is associated with reduced risk of conversion to multiple sclerosis over six months, according to a study published in the June 1 issue of the New England Journal of Medicine.

Luanne M. Metz, M.D., from the Cumming School of Medicine and the Hotchkiss Brain Institute in Calgary, Canada, and colleagues randomized 142 participants who had had their first demyelinating symptoms within the previous 180 days to receive 100 mg minocycline (72 participants) or placebo (70 participants) until a diagnosis of multiple sclerosis was established or until 24 months after randomization.

The researchers found that the unadjusted risk of conversion to multiple sclerosis within six months after randomization was 61.0 and 33.4 percent in the placebo and minocycline groups, respectively (difference, 27.6 percent; 95 percent confidence interval, 11.4 to 43.9; P = 0.001). The difference in the risk of conversion to multiple sclerosis within six months after randomization was 18.5 percentage points, after adjustment for the number of enhancing lesions at baseline (95 percent confidence interval, 3.7 to 33.3; P = 0.01). At the 24-month secondary outcome time point, the unadjusted risk difference was not significant (P = 0.06).

"The risk of conversion from a clinically isolated syndrome to multiple sclerosis was significantly lower with minocycline than with placebo over six months but not over 24 months," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »